GV News & Events

Visionary Holdings announced that it has entered into an investment cooperation agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed $20M strategic investment for the company's Qingdao anti-aging project in Qingdao West Coast New Area, China. "Under the agreement, the parties plan to establish a project company to serve as the operating entity for the collaboration. The project company is expected to establish the 'GV China Anti-Aging Research Center' in Qingdao West Coast New Area, with an initial focus on research and translational development in areas including cell therapy and biologics. In parallel, the project company is also expected to begin building out a 'GV Anti-Aging Health Management Center' chain model in China, initially with a focus on the Shandong market and with the goal of introducing internationally aligned products and service standards. According to the cooperation framework, the investor intends to make a total investment of no less than $20M into the project company in two phases. The initial phase is structured around three milestone-based payments: 30% upon establishment of the project company and opening of its capital account, 40% upon completion of renovation of the research center and installation of equipment, and the final 30% after the first flagship center opens and generates its first month of operating data. A second-phase investment of $10M is contemplated subject to the Company's subsequent development progress," the company stated.

Visionary Holdings entered into a strategic cooperation agreement with Zhejiang Chushanji Digital Technology Co. According to information provided by Chushanji, the company currently operates an extensive offline commercial network spanning 5 provinces and 105 district- and county-level markets in China, covering nearly 10,000 stores. Pursuant to the agreement, Chushanji is expected to assist Visionary in the marketing, channel development, distribution, and sales support of the Company's V-series anti-aging products in China. By leveraging Chushanji's existing offline business network and operational resources, the cooperation is intended to facilitate product promotion, channel penetration, and potential customer conversion across selected medical aesthetics and wellness service locations. Chushanji has developed an offline service network through its ongoing business activities, which may provide Visionary with access to a broad base of service locations and consumer touchpoints. Through this cooperation, the Company expects to explore scalable approaches for expanding market awareness and supporting the commercialization of its V-series anti-aging products in the Chinese market. Based on preliminary internal estimates, the Company believes that, if the collaboration progresses as expected and market adoption is achieved, annual revenue contribution from related products could potentially reach a range of approximately $10M to $15M over time.

Visionary Holdings provided its 2026-2027 business outlook and strategic growth priorities as the Company continues executing its expansion into global healthcare and medical aesthetics markets. The company said, "Over the past year, Visionary has progressively repositioned its strategic focus toward higher-margin healthcare services and medical aesthetics businesses. The Company has previously announced initiatives aimed at expanding into international healthcare markets, including North America and Europe, through product commercialization, healthcare service collaborations, and international distribution partnerships. Management believes that the global medical aesthetics and anti-aging industry continues to demonstrate strong long-term growth potential, driven by increasing consumer demand for advanced aesthetic treatments and regenerative healthcare solutions. Management believes that the period from 2026 through 2027 may represent an important stage in the Company's commercialization and international expansion within the healthcare and medical aesthetics sectors. Visionary expects that the commercialization of its RAMU anti-aging product line, part of the Company's medical aesthetics and regenerative healthcare portfolio, may become an important driver of revenue growth during this period. Based on current market expansion plans and distribution arrangements, management believes that RAMU-related product sales could potentially reach approximately $30M in annual sales, subject to market conditions, regulatory approvals, and operational execution. The Company also expects that these business segments may deliver relatively higher gross margins compared with certain legacy businesses, reflecting the premium positioning of medical aesthetics and anti-aging products within the global healthcare and wellness market. Revenue recognition and financial results will be determined in accordance with applicable accounting standards and the Company's financial reporting cycles."

The company said, "Building on previously announced initiatives, the Company plans to continue expanding its presence in international healthcare markets, including North America and Europe, through product commercialization, distribution partnerships, and healthcare service collaborations. Visionary intends to accelerate the commercialization of its RAMU anti-aging product line, targeting premium medical aesthetics and regenerative healthcare applications.The Company plans to further develop healthcare service platforms that combine medical aesthetics products, wellness services, and advanced biotechnology applications."